Schneyer Mark C. 4
4 · ACADIA PHARMACEUTICALS INC · Filed Sep 16, 2025
Insider Transaction Report
Form 4
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Transactions
- Award
Common Stock
2025-09-12+6,815→ 46,945 total - Sale
Common Stock
2025-09-15$23.65/sh−3,498$82,728→ 43,447 total
Footnotes (2)
- [F1]Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).